KCM
INBX

Kennedy Capital Management’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Kennedy Capital Management’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-6,991
Closed -$266K – 788
2023
Q4 		$266K Buy
+6,991
New +$150K 0.01% 661

Other funds holding INBX

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Kennedy Capital Management's INBX Position: Q1 2024 in Review

Kennedy Capital Management sold out of Inhibrx, Inc. Common Stock (INBX) in Q1 2024, closing a stake of 6,991 shares — an estimated $266K sold.

Kennedy Capital Management first reported a position in INBX in Q4 2023 and held it in 1 quarter. The position peaked at $266K in Q4 2023. 126 funds tracked by Wall St. Rank hold INBX as of Q1 2024.

  • Kennedy Capital Management reported no remaining Inhibrx, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Kennedy Capital Management sold 6,991 Inhibrx, Inc. Common Stock shares in Q1 2024, an estimated $266K.
  • Kennedy Capital Management first reported a position in Inhibrx, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
  • Kennedy Capital Management's Inhibrx, Inc. Common Stock position peaked at $266K in Q4 2023.
  • 126 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q1 2024.

Based on Kennedy Capital Management's 13F filing for Q1 2024, filed 15 May 2024.